GlaxoSmithKline‘s (NYSE:GSK) new chief executive, Emma Walmsley, signaled in April that she plans to cut programs in the company’s pharmaceutical pipeline that aren’t generating enough value, including older antibiotics.
“We’ll need to be switching off some areas,” Walmsley said, according to Reuters. She is slated to detail her plans this week when she presents second quarter financial results, the newswire reported.
Get the full story at our sister site, Drug Delivery Business News.
The post New GSK chief executive to refocus pipeline appeared first on MassDevice.